Although preclinical studies are warranted, our findings also suggest that targeting JNK in combination with FU- or GEM-based regimens may be a promising approach to elimination of pancreatic CSCs and therefore successful treatment of pancreatic cancer. The gene discussed is MAPK8; the disease is familial pancreatic carcinoma.